What's Going On With Capricor Therapeutics Stock Friday?
What's Going On With Capricor Therapeutics Stock Friday?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the treatment of duchenne muscular dystrophy (DMD).
Capricor Therapeutics公司（納斯達克:CAPR）的股票週五交易上漲。該公司宣佈使用deramiocel治療杜氏肌萎縮症（DMD）具有長期益處。
What Happened: The biotechnology company said deramiocel increased cardiac function based on several different measures.
發生了什麼: 這家生物技術公司表示，根據多種不同的措施，deramiocel提高了心臟功能。
The study found improvements in left ventricular ejection fraction, left ventricular end systolic volume and left ventricular end diastolic volume. Capricor stated that these measures are considered highly applicable when projecting future outcomes.
該研究發現，左心室射血分數、左心室收縮末期容積和左心室舒張末期容積均有所改善。Capricor表示，這些措施在預測未來結果時被認爲是高度適用的。
The trial also demonstrated increased skeletal function, particularly increased performance of upper limb.
試驗還表明了骨骼功能的增強，特別是上肢的性能提高。
The company based these positive findings off the ongoing HOPE-2 open label extension study. Capricor is expected to present these results at the Parent Project Muscular Dystrophy (PPMD) Annual Conference on Saturday.
該公司基於正在進行的HOPE-2開放標籤延長研究得出了這些積極的發現。預計Capricor將在週六的Parent Project Muscular Dystrophy (PPMD)年度會議上展示這些結果。
Related Link: Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
相關鏈接: 華爾街上最準確的分析師們對3只具有3%以上股息收益率的醫療保健股票發表了看法
CAPR Price Action: Capricor Therapeutics shares are trading 4.39% higher at $4.84 at the time of writing per data from Benzinga Pro.
CAPR股價行動：根據Benzinga Pro的數據，Capricor Therapeutics股票在撰寫本文時交易上漲4.39%，報4.84美元。
Image: Shutterstock/ REDPIXEL.PL
圖片來源: shutterstock/REDPIXEL.PL
譯文內容由第三人軟體翻譯。